Printable Biography

Biography

Robert Feltoon’s practice covers a broad spectrum of complex business litigation on behalf of Fortune 500 companies as well as smaller companies and individuals. A significant percentage of Bob’s practice is in New Jersey. He also continues to practice in New York, where he spent the first 10 years of his career as a litigation associate at Cravath, Swaine & Moore LLP.

Since joining Conrad O’Brien in 1990, Bob continually has represented IBM Corporation in cases in Pennsylvania and New Jersey and, more recently, in New York. His cases for IBM have involved, among other areas, contract disputes with vendors and customers, employment claims by former employees, and environmental claims. For example, he successfully represented IBM in a case brought by a potential subcontractor under a contract between IBM and the Department of Defense. Trianco, LLC v. IBM Corp., 466 F. Supp. 2d 600 (E.D. Pa. 2006), aff’d in relevant part, 2008 WL 876355 (3d Cir. 2008).

Bob also represents the Progressive Group of Insurance Companies in numerous cases in Pennsylvania, New Jersey and New York. Many of those cases involve class action claims raising significant issues under various “no fault” reimbursement programs. As an example, he took the lead on behalf of a group of insurer defendants in a New York case involving reimbursements for multiple MRI’s conducted at a single session. The trial court granted defendants’ motion for summary judgment and the matter is now on appeal, where Bob will again take the lead on behalf of all defendants. Brentwood Pain & Rehab. Serv., P.C. v. Allstate Ins. Co., 508 F. Supp. 2d 278 (S.D.N.Y. 2007).

Bob currently is one of the senior counsel for Qualcomm Inc. in antitrust litigation pending in the District of New Jersey brought by Broadcom Corporation. Broadcom Corp. v. Qualcomm, Inc., No. 05-3350 (D.N.J.).  He currently is lead counsel, along with firm chairman Jim Rohn, for two current and two former senior officers of Merck & Co., Inc. in shareholder derivative litigation arising from Merck’s marketing of the drug Vioxx. Fagin v. Scolnick, docket L-3406-07 (N.J. Super. Ct.).